June 9, 2020 / 1:26 PM / a month ago

BRIEF-Karyopharm Announces Dosing Of Glioblastoma Patient In Phase 1/2 Study Of Selinexor Combo Therapy

June 9 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM ANNOUNCES DOSING OF FIRST PATIENT IN A PHASE 1/2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below